The pharmacokinetics and pharmacodynamics of fosinoprilat, the diacid of fosinopril sodium, a new angiotensin-converting enzyme (ACE) inhibitor, were investigated after the oral administration of 10 mg of fosinopril sodium to 6 chronic ambulatory peritoneal dialysis (CAPD) patients. The results from 1 patient are reported separately because of the presence of concomitant liver dysfunction.
The mean t1/2, Cmax, tmax, and AUC values for 5 of the CAPD patients were 19.5 h, 202 ng·ml−1, 4.8 h, and 3.19 μg·h·ml−1, respectively. Values for 1 CAPD patient with liver dysfunction were t1/2 of 65.4 h, Cmax of 182 ng·ml−1, tmax of 9 h, and AUC of 18.1 μg·h·ml−1. Peritoneal clearance of fosinoprilat was negligible, ranging from 0.07 to 0.23 ml·min−1.
Serum ACE activity remained significantly suppressed at 24 and 48 h after fosinopril sodium administration with mean decreases from baseline of 94.2% and 70.6%, respectively. ACE activity was suppressed to an even greater degree in the patient with liver dysfunction, remaining 97% inhibited 72 h after drug administration. Plasma renin activity (PRA) increased and plasma aldosterone concentrations decreased following drug administration. Mean arterial pressure did not change appreciably throughout the study. Dosage reductions may not be necessary in the majority of dialysis patients.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Duchin KL, Herman TS, O'Leary K, Tu J, Nichola P (1987) Steady-state (SS) kinetics of fosinopril in hypertensive patients. Clin Pharmacol Ther 41: 227
Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M (1988) Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 25: 9–15
Gehr TWB, Sica DA, Brater DC, Davis J, Fakhry I (1988) Furosemide pharmacokinetics and pharmacodynamics in renal transplantation. Clin Pharmacol Ther 43: 547–553
Swanson BN, Stauber KL, Alpaugh WC, Weinstein SH (1985) Radioenzymatic assay of angiotensin-converting enzyme inhibitors in plasma and urine. Anal Biochem 148: 401–407
Fuhr JJ, Daczmarczyk J, Kruttgen CD (1955) Eine einfache colorimetrische Methode zur Inulinbestimmung für Nieren-Clearance-Untersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr 33: 729–730
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2. ed. Dekker, New York, pp 409–417
Van Schaik BAM, Geyskes GG, Boer P (1976) Lisinopril in hypertensive patients with and without renal failure. Eur J Clin Pharmacol 32: 11–16
Donnelly R, Meredith PA, Elliott HL, Reid JL (1990) Kinetic-dynamic relations and individual responses to enalapril. Hypertension 15: 301–309
Metzler CM, Weiner DL (1989) PCNONLIN user's guide, 3 ed. Statistical Consultants, Lexingtion, KY
Duchin K, Kripalani K, Kramer P, Sica DA (1989) Disposition and pharmacodynamics of fosinopril sodium (FS) and its diacid in hemodialysis (HD) patients. Kidney Int 35: 245
Drummer OH, Workman BS, Miach PJ, Jarrott B, Louis WJ (1987) The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: Comparison with patients with normal renal function. Eur J Clin Pharmacol 32: 267–271
Kelly JG, Doyle GD, Carmody M, Glover DR, Cooper WD (1988) Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. Br J Clin Pharmacol 26: 781–786
Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yonogowa N (1991) Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 49: 454
Fujimura A, Kajiyama J, Ebihara A, Iwashita K, Nomura Y, Kawahara Y (1986) Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. Nephron 44: 324–328
Biollaz J, Schelling JL, Jocot des Combes B, Brunner DB, Desponds G, Brunner HR, Ulm EH, Hichens M, Gomez HJ (1982) Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol 14: 363–368
Johnston CI, Jackson BJ, Larmour I, Cubella R, Casley D (1984) Plasma enalapril levels and hormonal effects after short- and longterm administration in essential hypertension. Br J Clin Pharmacol 18: 233S-238S
Holford NHG, Steiner LB (1981) Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429–453
Zager PG, Frey HJ, Gerdes BG (1983) Plasma 18-hydroxycorticosterone during continuous ambulatory peritoneal dialysis. J Lab Clin Med 102: 604–612
Glasson P, Favre H, Vallotton M (1982) Response of blood pressure and the renin-angiotensin-aldosterone system to chronic ambulatory peritoneal dialysis in hypertensive end-stage renal failure. Clin Sci 63: 207S-209S
Fruncillo RJ, Rocci ML, Vlasses PH Jr., Mojaverian P, Shepley K, Clementi RA, Oren A, Smith RD, Till AE, Riley LJ Jr., Krishna G, Narins RG, Ferguson RK (1987) Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int 31 [Suppl 20]: S117-S122
These studies were supported in part by the Bristol-Myers Squibb Pharmaceutical Research Institute and by NIH grant M01-RR00065
About this article
Cite this article
Gehr, T.W.B., Sica, D.A., Grasela, D.M. et al. Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol 41, 165–169 (1991). https://doi.org/10.1007/BF00265911
- peritoneal dialysis